Mohammed Ansari, DO
Psychiatry · Tamarac, FLNPI 1811438682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 31.0% of the total. Reporting peaked in 2020 at $93 and has fallen 63.0% since, to $34 in 2024. That places this record below the midpoint for psychiatry clinicians in FL, where the typical reported total is $420.
Across 12 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$77
- Vanda Pharmaceuticals Inc.$44
- Otsuka America Pharmaceutical, Inc.$39
- Avanir Pharmaceuticals, Inc.$36
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22
- Eisai Inc.$18
- plus $13 from 1 others
What the payments were for
- Food & beverage$250100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$250 in reported general payments places this provider in the 40th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 11 | $5,554 |
| Duloxetine Hcl | 52 | $1,955 |
| Bupropion XlBupropion Hcl | 32 | $731 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $506 |
| Trazodone Hcl | 42 | $265 |
| Sertraline Hcl | 29 | $258 |
| Mirtazapine | 16 | $190 |
| Buspirone Hcl | 17 | $160 |
| Lamotrigine | 14 | $152 |
| Hydroxyzine Hcl | 21 | $142 |
| Escitalopram Oxalate | 31 | $120 |
| Aripiprazole | 11 | $119 |
| Clonazepam | 22 | $111 |
| Bupropion Hcl SrBupropion Hcl | 13 | $92 |
| Fluoxetine Hcl | 14 | $52 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Tamarac
- Rishi KakarTamarac$94K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.